Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

This study is looking for adults aged 18 or older who have been diagnosed with multiple myeloma. Your cancer must have come back or not responded well to at least one previous treatment that included a drug called lenalidomide. We also need to be able to measure your cancer in some way, such as through blood or urine tests.

Your general health should be good enough to participate, meaning you can carry out most daily activities without too much difficulty. If you've had a stem cell transplant before, that's generally okay, as long as it was more than 100 days ago and you don't have any serious infections. We also need any side effects from your previous treatments to have mostly cleared up.

You would not be able to join if you have certain other conditions, like active plasma cell leukaemia, severe nerve problems, or specific organ issues that could make the treatment unsafe for you. Both men and women will need to agree to use effective contraception during the study.

If you decide to take part, you'll be assigned to one of two treatment groups – either the group receiving belantamab mafodotin, pomalidomide, and dexamethasone, or the group receiving bortezomib, pomalidomide, and dexamethasone. The treatments involve taking medications, which could be in pill form or given as injections/infusions, depending on the specific drug.

You'll have regular visits to the hospital for check-ups, blood tests, and scans to monitor your health and how the treatment is working. These visits will help the study doctors keep a close eye on your progress and any potential side effects. The total duration of your participation will depend on how you respond to the treatment and the study plan, but you will be kept informed every step of the way. All participants will be carefully followed up, even after their active treatment period ends.